ReviewMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2025
Endometrial Cancer: A Daily Clinical Practice Guide for Radiologists.
Review in Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Letter to the Editor about "Endometrial Cancer: A Daily Clinical Practice Guide for Radiologists" Published Online: August 20, 2025.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- Discordant p53 and BRG1 expression in synchronous low-grade uterine endometrioid carcinoma and SMARCA4-deficient ovarian undifferentiated carcinoma: a case report.BMC women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is projected to become the third most common cancer and the fourth leading cause of cancer-related deaths among women by 2040, with the most substantial increases observed in non-Hispanic Black, Hispanic, and Asian populations. The International Federation of Gynecology and Obstetrics (FIGO) 2023 classification introduces key updates, including a refined staging system incorporating molecular markers for improved risk stratification. MRI plays a critical role in treatment planning by evaluating the extent of the disease, determining eligibility for fertility-preserving options, guiding radiotherapy planning, and supporting follow-up care. It is also essential for distinguishing EC from cervical cancer. Notable revisions in the FIGO 2023 staging guidelines focus on assessing myometrial invasion, identifying synchronous or metastatic ovarian tumors, and evaluating peritoneal involvement. Recurrence typically occurs within the first 2 years, with common sites including the vaginal vault and lymph nodes, where MRI remains the preferred imaging modality. While CT is routinely employed to assess metastatic disease,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.